Our pricing is based on prescribed treatment plans, with options starting as low as $99 per month for semaglutide and $180 per month for tirzepatide, depending on provider-directed dosing.
SHRED Weightloss offers prescription-based care with no insurance, no subscriptions, and no hidden fees. HSA payments are accepted, and Afterpay is available for flexible payment options.
All individuals begin with a one-on-one telehealth consultation with our licensed medical provider. This visit is used to determine whether prescription GLP-1 medication is clinically appropriate based on your health history, current medications, and weight loss goals.
During this consultation, the provider will answer your questions, explain available treatment options, and outline next steps if care is recommended. Medical decisions are made entirely by the provider — not selected by the patient.
There is no charge for the consultation.
A $50 new patient fee is only applied if you move forward as a patient.
Before your appointment, you’ll complete a secure intake form. During your consultation, the provider reviews your medical history, current medications, and weight loss goals. This ensures care is safe, appropriate, and tailored to you from the start.
During your telehealth visit, the provider explains available prescription GLP-1 options and how they work. Based on your evaluation, the provider determines whether medication is appropriate and which option may be the best fit. All recommendations are made by the provider — not selected by the patient.
If treatment is approved, you’ll receive clear guidance on dosing, follow-up, and how medication is fulfilled through the pharmacy. You’ll have the opportunity to ask questions and understand what ongoing medical support looks like.
There are no subscriptions, no auto-billing, and no long-term commitments.
Semaglutide is a well-established prescription GLP-1 medication commonly used in medical weight loss care. It is often selected for a gradual, steady approach when appropriate.
This 2ml vial (200 total units) is most commonly prescribed for patients beginning GLP-1 therapy or starting at lower weekly doses. Based on provider-directed dosing, this vial may last approximately 12–16 weeks.
Semaglutide is often selected for patients early in treatment who are titrating gradually while monitoring tolerance and response.
Tirzepatide is a prescription GLP-1 medication that works on multiple appetite-related pathways and may be prescribed based on an individual medical evaluation. It is often considered for patients who may benefit from enhanced appetite regulation and metabolic support when clinically appropriate.
Each vial contains 100 units per 1ml, and dosing is determined exclusively by a licensed medical provider. Estimated duration varies based on individualized dosing, treatment plan, and patient response.
This 2ml vial contains 200 total units of tirzepatide and is most commonly prescribed for patients beginning treatment or starting at lower weekly doses. Based on provider-directed dosing, this vial may last approximately 5–10 weeks. Duration varies depending on individual titration, tolerance, and clinical response. This option is often used early in treatment while the provider evaluates how the body responds to therapy.
This 3ml vial contains 300 total units of tirzepatide and is typically prescribed for patients who are continuing treatment at a stable dose. Based on provider-directed dosing, this vial may last approximately 6–15 weeks. Duration varies depending on individual titration, tolerance, and treatment response.
This option is often selected by patients established on therapy who prefer fewer pharmacy refills while maintaining consistent progress.
This 4ml vial contains 400 total units of tirzepatide and is typically prescribed for patients established on sustained or higher dosing plans. Based on provider-directed dosing, this vial may last approximately 4–8 weeks.
Duration varies depending on individual dosing, treatment response, and clinical evaluation, and this option is commonly used as part of an ongoing treatment plan under medical supervision.